SmithKline Beecham Laboratories Pharmaceutiques
Records under this name other than patents SmithKline Beecham Laboratories Pharmaceutiques holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to SmithKline Beecham Laboratories Pharmaceutiques
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,274,172 | Therapeutic effervescent compositions Formerly held Term ended Term ended Sep 3, 2018 · USPTO record | Term ended | Term ended Sep 3, 2018 | USPTO record |
| US 6,506,758 | Indole Derivatives Useful A.O. for the Treatment of Osteoporosis Lapsed on the fee record Ended Jan 14, 2015 · Medium confidence | Lapsed on the fee record | Ended Jan 14, 2015 | Medium confidence |
| US 6,316,219 | Compounds Lapsed on the fee record Ended Nov 13, 2013 · USPTO record | Lapsed on the fee record | Ended Nov 13, 2013 | USPTO record |
| US 6,200,776 | Polynucleotides encoding human sodium bicarbonate cotransporters Lapsed on the fee record Ended Mar 13, 2013 · USPTO record | Lapsed on the fee record | Ended Mar 13, 2013 | USPTO record |
| US 6,197,069 | Adrenomedullin receptor polynucleotides Lapsed on the fee record Ended Mar 6, 2013 · USPTO record | Lapsed on the fee record | Ended Mar 6, 2013 | USPTO record |
| US 6,780,875 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists Lapsed on the fee record Ended Aug 24, 2012 · USPTO record | Lapsed on the fee record | Ended Aug 24, 2012 | USPTO record |
| US 6,096,517 | Human kidney sodium bicarbonate transporter (HNBC1A) polynucleotides Lapsed on the fee record Ended Aug 1, 2012 · USPTO record | Lapsed on the fee record | Ended Aug 1, 2012 | USPTO record |
| US 6,699,889 | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart Lapsed on the fee record Ended Mar 2, 2012 · USPTO record | Lapsed on the fee record | Ended Mar 2, 2012 | USPTO record |
| US 6,613,770 | Quinoline derivatives as NK-2 and NK-3 receptor ligands Lapsed on the fee record Ended Sep 2, 2011 · USPTO record | Lapsed on the fee record | Ended Sep 2, 2011 | USPTO record |
| US 6,570,037 | Nitro-benzamides useful as anti-arrhythmic agents Lapsed on the fee record Ended May 27, 2011 · USPTO record | Lapsed on the fee record | Ended May 27, 2011 | USPTO record |